메뉴 건너뛰기




Volumn 74, Issue 16, 2014, Pages 1849-1870

Current and emerging pharmacotherapeutic options for irritable bowel syndrome

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; BILE ACID SEQUESTRANT; CIMETROPIUM; CITALOPRAM; DESIPRAMINE; DEXTRIN; FLUOXETINE; IMIPRAMINE; ISPAGULA; KAPPA OPIATE RECEPTOR AGONIST; LUBIPROSTONE; MEBEVERINE; MELATONIN; METHYLCELLULOSE; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; OTILONIUM BROMIDE; PAROXETINE; PEPPERMINT OIL; POLYCARBOPHIL; PROBIOTIC AGENT; SCOPOLAMINE; SEROTONIN AGONIST; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; UNINDEXED DRUG; YOGHURT;

EID: 84921935845     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0292-7     Document Type: Review
Times cited : (23)

References (110)
  • 2
  • 4
    • 84862651150 scopus 로고    scopus 로고
    • Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis
    • 22426087 (Epub 2012 Mar 15)
    • Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.e4. (Epub 2012 Mar 15).
    • (2012) Clin Gastroenterol Hepatol , vol.10 , Issue.7 , pp. 712-721e4
    • Lovell, R.M.1    Ford, A.C.2
  • 7
    • 84865430465 scopus 로고    scopus 로고
    • Diagnostic criteria in IBS: Useful or not?
    • Mearin F, Lacy BE. Diagnostic criteria in IBS: useful or not? Neurogastroenterol Motil. 2010;24:791-801.
    • (2010) Neurogastroenterol Motil , vol.24 , pp. 791-801
    • Mearin, F.1    Lacy, B.E.2
  • 8
    • 0018174715 scopus 로고
    • Towards positive diagnosis of the irritable bowel
    • 698649 1:STN:280:DyaE1M%2Fit1ehsg%3D%3D 1607467
    • Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2(6138):653-4.
    • (1978) Br Med J , vol.2 , Issue.6138 , pp. 653-654
    • Manning, A.P.1    Thompson, W.G.2    Heaton, K.W.3    Morris, A.F.4
  • 9
    • 0033789462 scopus 로고    scopus 로고
    • A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome
    • 11051354 1:STN:280:DC%2BD3crgt12isw%3D%3D
    • Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ 3rd. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol. 2000;95(10):2816-24.
    • (2000) Am J Gastroenterol , vol.95 , Issue.10 , pp. 2816-2824
    • Saito, Y.A.1    Locke, G.R.2    Talley, N.J.3    Zinsmeister, A.R.4    Fett, S.L.5    Melton, L.J.6
  • 12
    • 84865417908 scopus 로고    scopus 로고
    • Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III
    • Dang J, Ardila-Hani A, Amichai MM, Chua K, Pimentel M. Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III. Neurogastroenterol Motil. 2012;24(9):853-e397.
    • (2012) Neurogastroenterol Motil , vol.24 , Issue.9 , pp. 853-e397
    • Dang, J.1    Ardila-Hani, A.2    Amichai, M.M.3    Chua, K.4    Pimentel, M.5
  • 13
    • 77953773581 scopus 로고    scopus 로고
    • Meta-analysis: Factors affecting placebo response rate in the irritable bowel syndrome
    • 20412064 1:CAS:528:DC%2BC3cXpslWls7s%3D
    • Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010;32:144-58.
    • (2010) Aliment Pharmacol Ther , vol.32 , pp. 144-158
    • Ford, A.C.1    Moayyedi, P.2
  • 14
    • 84865618766 scopus 로고    scopus 로고
    • Meditation over medication for irritable bowel syndrome? on exercise and alternative treatments for irritable bowel syndrome
    • 22661301
    • Asare F, Störsrud S, Simrén M. Meditation over medication for irritable bowel syndrome? On exercise and alternative treatments for irritable bowel syndrome. Curr Gastroenterol Rep. 2012;14(4):283-9.
    • (2012) Curr Gastroenterol Rep. , vol.14 , Issue.4 , pp. 283-289
    • Asare, F.1    Störsrud, S.2    Simrén, M.3
  • 16
    • 0038726415 scopus 로고    scopus 로고
    • Validation of irritable bowel syndrome Global Improvement Scale: An integrated symptom end point for assessing treatment efficacy
    • 12870789
    • Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E. Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci. 2003;48(7):1317-23.
    • (2003) Dig Dis Sci , vol.48 , Issue.7 , pp. 1317-1323
    • Gordon, S.1    Ameen, V.2    Bagby, B.3    Shahan, B.4    Jhingran, P.5    Carter, E.6
  • 17
    • 33745659814 scopus 로고    scopus 로고
    • Systematic review: The efficacy of treatments for irritable bowel syndrome - A European perspective
    • 16842448 1:CAS:528:DC%2BD28Xosl2gtLc%3D (Review)
    • Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther. 2006;24(2):183-205 (Review).
    • (2006) Aliment Pharmacol Ther , vol.24 , Issue.2 , pp. 183-205
    • Tack, J.1    Fried, M.2    Houghton, L.A.3    Spicak, J.4    Fisher, G.5
  • 18
    • 57749192461 scopus 로고    scopus 로고
    • Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis
    • Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;13(337):a2313.
    • (2008) BMJ , vol.13 , Issue.337 , pp. 2313
    • Ford, A.C.1    Talley, N.J.2    Spiegel, B.M.3    Foxx-Orenstein, A.E.4    Schiller, L.5    Quigley, E.M.6    Moayyedi, P.7
  • 19
    • 70349090574 scopus 로고    scopus 로고
    • Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial
    • Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;27(339):b3154.
    • (2009) BMJ , vol.27 , Issue.339 , pp. 3154
    • Bijkerk, C.J.1    De Wit, N.J.2    Muris, J.W.3    Whorwell, P.J.4    Knottnerus, J.A.5    Hoes, A.W.6
  • 21
    • 0242496957 scopus 로고    scopus 로고
    • Constipation - Modern laxative therapy
    • 14505158 1:STN:280:DC%2BD3srhslGrsQ%3D%3D
    • Klaschik E, Nauck F, Ostgathe C. Constipation - modern laxative therapy. Support Care Cancer. 2003;11(11):679-85.
    • (2003) Support Care Cancer , vol.11 , Issue.11 , pp. 679-685
    • Klaschik, E.1    Nauck, F.2    Ostgathe, C.3
  • 22
    • 70549086902 scopus 로고    scopus 로고
    • Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics)
    • Khalif IL, Quigley EM, Makarchuk PA, Golovenko OV, Podmarenkova LF, Dzhanayev YA. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). J Gastrointest Liver Dis. 2009;18(1):17-22.
    • (2009) J Gastrointest Liver Dis. , vol.18 , Issue.1 , pp. 17-22
    • Khalif, I.L.1    Quigley, E.M.2    Makarchuk, P.A.3    Golovenko, O.V.4    Podmarenkova, L.F.5    Dzhanayev, Y.A.6
  • 23
    • 79960563170 scopus 로고    scopus 로고
    • Randomised clinical trial: Otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome
    • 21679214
    • Clavé P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34(4):432-42.
    • (2011) Aliment Pharmacol Ther. , vol.34 , Issue.4 , pp. 432-442
    • Clavé, P.1    Acalovschi, M.2    Triantafillidis, J.K.3
  • 24
    • 80054942059 scopus 로고    scopus 로고
    • The evaluation of otilonium bromide treatment in Asian patients with irritable bowel syndrome
    • 22148110 3228981
    • Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The evaluation of otilonium bromide treatment in Asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17(4):402-10.
    • (2011) J Neurogastroenterol Motil. , vol.17 , Issue.4 , pp. 402-410
    • Chang, F.Y.1    Lu, C.L.2    Luo, J.C.3    Chen, T.S.4    Chen, M.J.5    Chang, H.J.6
  • 25
    • 84902476444 scopus 로고    scopus 로고
    • Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis
    • Khanna R, Macdonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2013.
    • (2013) J Clin Gastroenterol
    • Khanna, R.1    Macdonald, J.K.2    Levesque, B.G.3
  • 26
    • 0041843834 scopus 로고    scopus 로고
    • Medically unexplained physical symptoms, anxiety and depression: A meta-analytic review
    • 12883101
    • Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety and depression: a meta-analytic review. Psychosom Med. 2003;65:528-33.
    • (2003) Psychosom Med , vol.65 , pp. 528-533
    • Henningsen, P.1    Zimmermann, T.2    Sattel, H.3
  • 27
    • 0036202892 scopus 로고    scopus 로고
    • Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?
    • 11910364
    • Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140-56.
    • (2002) Gastroenterology , vol.122 , pp. 1140-1156
    • Whitehead, W.E.1    Palsson, O.2    Jones, K.R.3
  • 28
    • 2442564082 scopus 로고    scopus 로고
    • Psychological factors in the irritable bowel syndrome
    • 14711602 1:STN:280:DC%2BD2c%2FhsVKnuw%3D%3D
    • Solmaz M, Kavuk I, Sayar K. Psychological factors in the irritable bowel syndrome. Eur J Med Res. 2003;8:549-56.
    • (2003) Eur J Med Res , vol.8 , pp. 549-556
    • Solmaz, M.1    Kavuk, I.2    Sayar, K.3
  • 29
    • 0037229534 scopus 로고    scopus 로고
    • Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health
    • 12488239 1:CAS:528:DC%2BD3sXntVSmsg%3D%3D
    • Chial HJ, Camilleri M, Burton D, et al. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol. 2003;284:G130-7.
    • (2003) Am J Physiol Gastrointest Liver Physiol , vol.284 , pp. 130-G137
    • Chial, H.J.1    Camilleri, M.2    Burton, D.3
  • 31
    • 70149108550 scopus 로고    scopus 로고
    • Duloxetine in the treatment of irritable bowel syndrome: An open-label pilot study
    • 1:CAS:528:DC%2BD1MXps1Kqs7w%3D
    • Brennan, et al. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol Clin Exp. 2009;24:423-8.
    • (2009) Hum Psychopharmacol Clin Exp , vol.24 , pp. 423-428
    • Brennan1
  • 32
    • 72949107621 scopus 로고    scopus 로고
    • Beyond tricyclics: New ideas for treating patients with painful and refractory functional gastrointestinal symptoms
    • 19956115
    • Drossman DA. Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol. 2009;104:2897-902.
    • (2009) Am J Gastroenterol , vol.104 , pp. 2897-2902
    • Drossman, D.A.1
  • 33
    • 61649089108 scopus 로고    scopus 로고
    • Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: Systematic review and meta-analysis
    • 19001059 1:CAS:528:DC%2BD1MXjsFGgt7s%3D
    • Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58(3):367-78.
    • (2009) Gut , vol.58 , Issue.3 , pp. 367-378
    • Ford, A.C.1    Talley, N.J.2    Schoenfeld, P.S.3    Quigley, E.M.4    Moayyedi, P.5
  • 34
    • 61849161180 scopus 로고    scopus 로고
    • A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome
    • 19213976 1:CAS:528:DC%2BD1MXitFClurk%3D
    • Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, Patkar AA. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009;50(1):78-86.
    • (2009) Psychosomatics. , vol.50 , Issue.1 , pp. 78-86
    • Masand, P.S.1    Pae, C.U.2    Krulewicz, S.3    Peindl, K.4    Mannelli, P.5    Varia, I.M.6    Patkar, A.A.7
  • 35
    • 0038418617 scopus 로고    scopus 로고
    • The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double blind, randomized, placebo-controlled study
    • 15017494 1:CAS:528:DC%2BD3sXlsVeltLg%3D
    • Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1(3):219-28.
    • (2003) Clin Gastroenterol Hepatol. , vol.1 , Issue.3 , pp. 219-228
    • Kuiken, S.D.1    Tytgat, G.N.2    Boeckxstaens, G.E.3
  • 36
    • 24344474273 scopus 로고    scopus 로고
    • The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: A double-blind randomized-controlled study
    • 16128675 1:CAS:528:DC%2BD2MXhtVykt73P
    • Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther. 2005;22(5):381-5.
    • (2005) Aliment Pharmacol Ther , vol.22 , Issue.5 , pp. 381-385
    • Vahedi, H.1    Merat, S.2    Rashidioon, A.3    Ghoddoosi, A.4    Malekzadeh, R.5
  • 37
    • 33746162460 scopus 로고    scopus 로고
    • A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome
    • 16401691 1:CAS:528:DC%2BD28Xot1Gqt7s%3D 1856276
    • Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55(8):1095-103.
    • (2006) Gut , vol.55 , Issue.8 , pp. 1095-1103
    • Tack, J.1    Broekaert, D.2    Fischler, B.3    Van Oudenhove, L.4    Gevers, A.M.5    Janssens6
  • 38
    • 40949125251 scopus 로고    scopus 로고
    • Clinical trial: The effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome
    • 1:CAS:528:DC%2BD1cXls1Kjtb0%3D
    • Vahedi H, Merat S, Momtahen S, Kazzazi AS, Ghaffari N, Olfati G, Malekzadeh R. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment PharmacolTher. 2008;27(8):678-84.
    • (2008) Aliment PharmacolTher. , vol.27 , Issue.8 , pp. 678-684
    • Vahedi, H.1    Merat, S.2    Momtahen, S.3    Kazzazi, A.S.4    Ghaffari, N.5    Olfati, G.6    Malekzadeh, R.7
  • 39
    • 37249086163 scopus 로고    scopus 로고
    • Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial
    • 17503182 1:CAS:528:DC%2BD1cXhs1eiur0%3D
    • Talley NJ, Kellow JE, Boyce P, et al. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 2008;53(1):108-15.
    • (2008) Dig Dis Sci. , vol.53 , Issue.1 , pp. 108-115
    • Talley, N.J.1    Kellow, J.E.2    Boyce, P.3
  • 40
    • 77953232580 scopus 로고    scopus 로고
    • Cognitive factors affect treatment response to medical and psychological treatments in functional bowel disorders
    • 20087332
    • Weinland, et al. Cognitive factors affect treatment response to medical and psychological treatments in functional bowel disorders. Am J Gastroenterol. 2010;105:1397-406.
    • (2010) Am J Gastroenterol , vol.105 , pp. 1397-1406
    • Weinland1
  • 41
    • 70449710320 scopus 로고    scopus 로고
    • Small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and meta-analysis
    • 19602448
    • Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279-86.
    • (2009) Clin Gastroenterol Hepatol. , vol.7 , Issue.12 , pp. 1279-1286
    • Ford, A.C.1    Spiegel, B.M.2    Talley, N.J.3    Moayyedi, P.4
  • 42
    • 34447104397 scopus 로고    scopus 로고
    • The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects
    • Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24e33.
    • (2007) Gastroenterology , vol.133 , pp. 24e33
    • Kassinen, A.1    Krogius-Kurikka, L.2    Makivuokko, H.3
  • 43
    • 80054857288 scopus 로고    scopus 로고
    • Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome
    • 21820992
    • Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792-801.
    • (2011) Gastroenterology , vol.141 , pp. 1792-1801
    • Rajilić-Stojanović, M.1    Biagi, E.2    Heilig, H.G.3    Kajander, K.4    Kekkonen, R.A.5    Tims, S.6    De Vos, W.M.7
  • 45
    • 77749318556 scopus 로고    scopus 로고
    • The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review
    • 19091823 1:STN:280:DC%2BC3c7mtVGguw%3D%3D
    • Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-32.
    • (2010) Gut , vol.59 , Issue.3 , pp. 325-332
    • Moayyedi, P.1    Ford, A.C.2    Talley, N.J.3    Cremonini, F.4    Foxx-Orenstein, A.E.5    Brandt, L.J.6    Quigley, E.M.7
  • 46
    • 65449172901 scopus 로고    scopus 로고
    • The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review the utility of probiotics in the treatment of IBS
    • 19277023 1:CAS:528:DC%2BD1MXktVKjt7c%3D
    • Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review the utility of probiotics in the treatment of IBS. Am J Gastroenterol. 2009;104:1033-49.
    • (2009) Am J Gastroenterol , vol.104 , pp. 1033-1049
    • Brenner, D.M.1    Moeller, M.J.2    Chey, W.D.3    Schoenfeld, P.S.4
  • 48
    • 84871502689 scopus 로고    scopus 로고
    • Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome
    • 22912552 3419998
    • Ducrotté P, Sawant P, Jayanthi V. Clinical trial: lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012-8.
    • (2012) World J Gastroenterol , vol.18 , Issue.30 , pp. 4012-4018
    • Ducrotté, P.1    Sawant, P.2    Jayanthi, V.3
  • 49
    • 84874633781 scopus 로고    scopus 로고
    • A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome
    • Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol. 2013;7(13):45.
    • (2013) BMC Gastroenterol. , vol.7 , Issue.13 , pp. 45
    • Roberts, L.M.1    McCahon, D.2    Holder, R.3    Wilson, S.4    Hobbs, F.D.5
  • 50
    • 70349682327 scopus 로고    scopus 로고
    • The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine
    • Krueger D, Gruber L, Buhner S, Zeller F, Langer R, Seidl S, et al. The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine. Neurogastroenterol Motil. 2009;21(11):1203-e110.
    • (2009) Neurogastroenterol Motil , vol.21 , Issue.11 , pp. 1203-e110
    • Krueger, D.1    Gruber, L.2    Buhner, S.3    Zeller, F.4    Langer, R.5    Seidl, S.6
  • 51
    • 11144332923 scopus 로고    scopus 로고
    • Meta-analysis: Phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast)
    • 15606389 1:STN:280:DC%2BD2cnjtVyksQ%3D%3D
    • Melzer J, Rösch W, Reichling J, Brignoli R, Saller R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther. 2004;20(11-12):1279-87.
    • (2004) Aliment Pharmacol Ther. , vol.20 , Issue.11-12 , pp. 1279-1287
    • Melzer, J.1    Rösch, W.2    Reichling, J.3    Brignoli, R.4    Saller, R.5
  • 52
    • 1342310220 scopus 로고    scopus 로고
    • Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled, multi-centre trial
    • 14984373 1:STN:280:DC%2BD2c%2FpsVyqtQ%3D%3D
    • Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther. 2004;19(3):271-9.
    • (2004) Aliment Pharmacol Ther , vol.19 , Issue.3 , pp. 271-279
    • Madisch, A.1    Holtmann, G.2    Plein, K.3    Hotz, J.4
  • 54
    • 0023732573 scopus 로고
    • Circadian rhythms in patients with abdominal pain syndromes
    • 3196244 1:STN:280:DyaL1M%2FmtFGiuw%3D%3D
    • Roberts-Thomson IC, Knight RE, Kennaway DJ, Pannall PR. Circadian rhythms in patients with abdominal pain syndromes. Aust N Z J Med. 1988;18(4):569-74.
    • (1988) Aust N Z J Med. , vol.18 , Issue.4 , pp. 569-574
    • Roberts-Thomson, I.C.1    Knight, R.E.2    Kennaway, D.J.3    Pannall, P.R.4
  • 55
    • 25444517619 scopus 로고    scopus 로고
    • Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: A randomised, double blind, placebo controlled study
    • 15914575 1:CAS:528:DC%2BD2MXhtFCksrfJ 1774717 (Epub 2005 May 24)
    • Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut. 2005;54(10):1402-7 (Epub 2005 May 24).
    • (2005) Gut , vol.54 , Issue.10 , pp. 1402-1407
    • Song, G.H.1    Leng, P.H.2    Gwee, K.A.3    Moochhala, S.M.4    Ho, K.Y.5
  • 56
    • 33644915873 scopus 로고    scopus 로고
    • Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome
    • 16393297 1:STN:280:DC%2BD28%2FgslSnug%3D%3D
    • Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23(1):191-6.
    • (2006) Aliment Pharmacol Ther. , vol.23 , Issue.1 , pp. 191-196
    • Khoshoo, V.1    Armstead, C.2    Landry, L.3
  • 57
    • 84883744403 scopus 로고    scopus 로고
    • Randomized clinical trial: Macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome
    • 23835436 1:CAS:528:DC%2BC3sXhsVSktrbI
    • Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508-15.
    • (2013) Am J Gastroenterol , vol.108 , Issue.9 , pp. 1508-1515
    • Chapman, R.W.1    Stanghellini, V.2    Geraint, M.3    Halphen, M.4
  • 58
    • 79951538087 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome
    • 19575740 1:STN:280:DC%2BC3cfptVGnuw%3D%3D
    • Awad RA, Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Dis. 2010;12(11):1131-8.
    • (2010) Colorectal Dis , vol.12 , Issue.11 , pp. 1131-1138
    • Awad, R.A.1    Camacho, S.2
  • 59
    • 58149103805 scopus 로고    scopus 로고
    • Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome - Results of two randomized, placebo-controlled studies
    • 19006537 1:STN:280:DC%2BD1M%2FlvFSntw%3D%3D
    • Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329-41.
    • (2009) Aliment Pharmacol Ther , vol.29 , Issue.3 , pp. 329-341
    • Drossman, D.A.1    Chey, W.D.2    Johanson, J.F.3    Fass, R.4    Scott, C.5    Panas, R.6
  • 60
    • 84856707088 scopus 로고    scopus 로고
    • Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation
    • 22251419 1:CAS:528:DC%2BC38XksFams7g%3D
    • Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35(5):587-99.
    • (2012) Aliment Pharmacol Ther , vol.35 , Issue.5 , pp. 587-599
    • Chey, W.D.1    Drossman, D.A.2    Johanson, J.F.3    Scott, C.4    Panas, R.M.5    Ueno, R.6
  • 61
    • 40949131857 scopus 로고    scopus 로고
    • Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation
    • 18248656 1:CAS:528:DC%2BD1cXls1Kjtbo%3D
    • Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2008;27(8):685-96.
    • (2008) Aliment Pharmacol Ther. , vol.27 , Issue.8 , pp. 685-696
    • Johanson, J.F.1    Drossman, D.A.2    Panas, R.3    Wahle, A.4    Ueno, R.5
  • 62
    • 78049283798 scopus 로고    scopus 로고
    • Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit
    • 20863829 1:CAS:528:DC%2BC3cXhtlKktbrL
    • Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010;649:328-35.
    • (2010) Eur J Pharmacol , vol.649 , pp. 328-335
    • Busby, R.W.1    Bryant, A.P.2    Bartolini, W.P.3
  • 63
    • 84888293106 scopus 로고    scopus 로고
    • Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5′-monophosphate
    • 23958540 1:CAS:528:DC%2BC3sXhsleju7rJ
    • Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5′-monophosphate. Gastroenterology. 2013;145:1334-46.
    • (2013) Gastroenterology , vol.145 , pp. 1334-1346
    • Castro, J.1    Harrington, A.M.2    Hughes, P.A.3
  • 64
  • 66
    • 4444245748 scopus 로고    scopus 로고
    • Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial
    • 15354280 1:CAS:528:DC%2BD2cXotFWrsrc%3D
    • Johanson JF, Wald A, Tougas G, Chey WD, Novick JS, Lembo AJ, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol. 2004;2(9):796-805.
    • (2004) Clin Gastroenterol Hepatol. , vol.2 , Issue.9 , pp. 796-805
    • Johanson, J.F.1    Wald, A.2    Tougas, G.3    Chey, W.D.4    Novick, J.S.5    Lembo, A.J.6
  • 68
    • 77951902634 scopus 로고    scopus 로고
    • Tegaserod and the risk of cardiovascular ischemic events: An observational cohort study
    • 20200325
    • Loughlin J, Quinn S, Rivero E, Wong J, Huang J, Kralstein J, et al. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. J Cardiovasc Pharmacol Ther. 2010;15(2):151-7.
    • (2010) J Cardiovasc Pharmacol Ther. , vol.15 , Issue.2 , pp. 151-157
    • Loughlin, J.1    Quinn, S.2    Rivero, E.3    Wong, J.4    Huang, J.5    Kralstein, J.6
  • 69
    • 84862758190 scopus 로고    scopus 로고
    • US Food and Drug Administration May 5, 2012 Accessed 01 2014
    • US Food and Drug Administration. Zelnorm (tegaserod maleate) information. May 5, 2012. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm103223.htm. Accessed 01 2014.
    • Zelnorm (Tegaserod Maleate) Information
  • 70
    • 44349130441 scopus 로고    scopus 로고
    • A placebo-controlled trial of prucalopride for severe chronic constipation
    • 18509121 1:CAS:528:DC%2BD1cXmsVKgsb0%3D
    • Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344-54.
    • (2008) N Engl J Med. , vol.358 , Issue.22 , pp. 2344-2354
    • Camilleri, M.1    Kerstens, R.2    Rykx, A.3    Vandeplassche, L.4
  • 71
    • 58149084950 scopus 로고    scopus 로고
    • Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-A 12 week, randomized, double-blind, placebo-controlled study
    • 19035970 1:STN:280:DC%2BD1M%2FlvFajsQ%3D%3D
    • Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12 week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315-28.
    • (2009) Aliment Pharmacol Ther , vol.29 , pp. 315-328
    • Quigley, E.M.1    Vandeplassche, L.2    Kerstens, R.3
  • 72
    • 61649119045 scopus 로고    scopus 로고
    • Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives
    • 18987031 1:CAS:528:DC%2BD1MXjsFGgt7o%3D
    • Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58:357-65.
    • (2009) Gut , vol.58 , pp. 357-365
    • Tack, J.1    Van Outryve, M.2    Beyens, G.3
  • 73
    • 0001300175 scopus 로고    scopus 로고
    • Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation (FC) or constipation-predominant irritable bowel syndrome (C-IBS)
    • Camilleri M, McKinzie S, Burton D, Thomforde GM, Zinsmeister AR, Bouras EP. Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation (FC) or constipation-predominant irritable bowel syndrome (C-IBS). Gastroenterology. 2000;118(4):A845.
    • (2000) Gastroenterology , vol.118 , Issue.4 , pp. 845
    • Camilleri, M.1    McKinzie, S.2    Burton, D.3    Thomforde, G.M.4    Zinsmeister, A.R.5    Bouras, E.P.6
  • 74
    • 41849096775 scopus 로고    scopus 로고
    • Clinical trial: Renzapride therapy for constipation-predominant irritable bowel syndrome - Multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting
    • 1:CAS:528:DC%2BD1cXlvVGqu7k%3D
    • George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome - multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment PharmacolTher. 2008;27(9):830-7.
    • (2008) Aliment PharmacolTher. , vol.27 , Issue.9 , pp. 830-837
    • George, A.M.1    Meyers, N.L.2    Hickling, R.I.3
  • 75
    • 77950574547 scopus 로고    scopus 로고
    • Clinical trial: Renzapride treatment of women with irritable bowel syndrome and constipation - A double-blind, randomized, placebo-controlled, study
    • 1:CAS:528:DC%2BC3cXmtFOgsL8%3D
    • Lembo AJ, Cremonini F, Meyers N, Hickling R. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study. Aliment PharmacolTher. 2010;31(9):979-90.
    • (2010) Aliment PharmacolTher. , vol.31 , Issue.9 , pp. 979-990
    • Lembo, A.J.1    Cremonini, F.2    Meyers, N.3    Hickling, R.4
  • 76
    • 33746162460 scopus 로고    scopus 로고
    • A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome
    • 16401691 1:CAS:528:DC%2BD28Xot1Gqt7s%3D 1856276
    • Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55(8):1095-103.
    • (2006) Gut. , vol.55 , Issue.8 , pp. 1095-1103
    • Tack, J.1    Broekaert, D.2    Fischler, B.3    Van Oudenhove, L.4    Gevers, A.M.5    Janssens, J.6
  • 77
    • 0023083675 scopus 로고
    • Loperamide treatment of the irritable bowel syndrome
    • 1:STN:280:DyaL2szhvFGmsA%3D%3D
    • Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol. 1987;130(Suppl):81-4.
    • (1987) Scand J Gastroenterol. , vol.130 , pp. 81-84
    • Hovdenak, N.1
  • 78
    • 0023087382 scopus 로고
    • Loperamide in treatment of irritable bowel syndrome - A double-blind placebo controlled study
    • Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study. Scand J Gastroenterol. 1987;130(Suppl):77-80.
    • (1987) Scand J Gastroenterol , vol.130 , pp. 77-80
    • Lavö, B.1    Stenstam, M.2    Nielsen, A.L.3
  • 79
    • 0029946003 scopus 로고    scopus 로고
    • A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome
    • 8734343 1:CAS:528:DyaK28XjsValsLo%3D
    • Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996;31(5):463-8.
    • (1996) Scand J Gastroenterol , vol.31 , Issue.5 , pp. 463-468
    • Efskind, P.S.1    Bernklev, T.2    Vatn, M.H.3
  • 80
    • 0021348189 scopus 로고
    • Role of loperamide and placebo in management of irritable bowel syndrome (IBS)
    • 6365490 1:STN:280:DyaL2c7jtFGjug%3D%3D
    • Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci. 1984;29(3):239-47.
    • (1984) Dig Dis Sci , vol.29 , Issue.3 , pp. 239-247
    • Cann, P.A.1    Read, N.W.2    Holdsworth, C.D.3    Barends, D.4
  • 81
    • 74549185684 scopus 로고    scopus 로고
    • Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers
    • Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, Mäkivuokko H, Kajander K, Palva A. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009;17(9):95.
    • (2009) BMC Gastroenterol. , vol.17 , Issue.9 , pp. 95
    • Krogius-Kurikka, L.1    Lyra, A.2    Malinen, E.3    Aarnikunnas, J.4    Tuimala, J.5    Paulin, L.6    Mäkivuokko, H.7    Kajander, K.8    Palva, A.9
  • 82
    • 77949441303 scopus 로고    scopus 로고
    • The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea
    • 19898648 1:CAS:528:DC%2BD1MXhtlCru7vL 2773752
    • Koo HL, Dupont HL, Huang DB. The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. Ther Clin Risk Manag. 2009;5:841-8.
    • (2009) Ther Clin Risk Manag. , vol.5 , pp. 841-848
    • Koo, H.L.1    Dupont, H.L.2    Huang, D.B.3
  • 83
    • 78650864077 scopus 로고    scopus 로고
    • Rifaximin therapy for patients with irritable bowel syndrome without constipation
    • 21208106 1:CAS:528:DC%2BC3MXisVaqsw%3D%3D
    • Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.
    • (2011) N Engl J Med. , vol.364 , Issue.1 , pp. 22-32
    • Pimentel, M.1    Lembo, A.2    Chey, W.D.3    Zakko, S.4    Ringel, Y.5    Yu, J.6
  • 84
    • 84855462831 scopus 로고    scopus 로고
    • The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis
    • 22045120 1:CAS:528:DC%2BC38XkslOmsg%3D%3D
    • Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107(1):28-35.
    • (2012) Am J Gastroenterol , vol.107 , Issue.1 , pp. 28-35
    • Menees, S.B.1    Maneerattannaporn, M.2    Kim, H.M.3    Chey, W.D.4
  • 85
    • 67449083400 scopus 로고    scopus 로고
    • Review of rifaximin as treatment for SIBO and IBS
    • 19243285 1:CAS:528:DC%2BD1MXitlWrtrY%3D
    • Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18(3):349-58.
    • (2009) Expert Opin Investig Drugs , vol.18 , Issue.3 , pp. 349-358
    • Pimentel, M.1
  • 86
    • 33748204679 scopus 로고    scopus 로고
    • Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: Sub analysis of a double-blind randomized controlled study
    • 16832617 1:CAS:528:DC%2BD28Xosleqsrs%3D
    • Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: sub analysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51(8):1297-301.
    • (2006) Dig Dis Sci , vol.51 , Issue.8 , pp. 1297-1301
    • Pimentel, M.1    Chatterjee, S.2    Chow, E.J.3    Park, S.4    Kong, Y.5
  • 88
    • 84899114664 scopus 로고    scopus 로고
    • Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation. A pooled analysis of randomized, double-blind, placebo-controlled trials
    • 24697851 1:CAS:528:DC%2BC2cXmsFajur8%3D 4112801
    • Schoenfeld P, Pimental M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation. A pooled analysis of randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39(10):1161-8.
    • (2014) Aliment Pharmacol Ther , vol.39 , Issue.10 , pp. 1161-1168
    • Schoenfeld, P.1    Pimental, M.2    Chang, L.3
  • 89
    • 0033625752 scopus 로고    scopus 로고
    • Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers
    • 10848662 1:CAS:528:DC%2BD3cXltFSltLg%3D
    • Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther. 2000;14(6):775-82.
    • (2000) Aliment Pharmacol Ther. , vol.14 , Issue.6 , pp. 775-782
    • Houghton, L.A.1    Foster, J.M.2    Whorwell, P.J.3
  • 90
    • 0034712539 scopus 로고    scopus 로고
    • Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
    • 10744088 1:CAS:528:DC%2BD3cXisFOnsLc%3D
    • Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355(9209):1035-40.
    • (2000) Lancet , vol.355 , Issue.9209 , pp. 1035-1040
    • Camilleri, M.1    Northcutt, A.R.2    Kong, S.3    Dukes, G.E.4    McSorley, D.5    Mangel, A.W.6
  • 91
    • 0034917335 scopus 로고    scopus 로고
    • A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
    • 11485506 1:CAS:528:DC%2BD3MXlvVGrtbo%3D
    • Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161(14):1733-40.
    • (2001) Arch Intern Med , vol.161 , Issue.14 , pp. 1733-1740
    • Camilleri, M.1    Chey, W.Y.2    Mayer, E.A.3    Northcutt, A.R.4    Heath, A.5    Dukes, G.E.6    McSorley, D.7    Mangel, A.M.8
  • 92
    • 13744263696 scopus 로고    scopus 로고
    • A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS
    • 15654790 1:CAS:528:DC%2BD2MXht12rur0%3D
    • Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100(1):115-23.
    • (2005) Am J Gastroenterol. , vol.100 , Issue.1 , pp. 115-123
    • Chang, L.1    Ameen, V.Z.2    Dukes, G.E.3    McSorley, D.J.4    Carter, E.G.5    Mayer, E.A.6
  • 93
    • 77950520996 scopus 로고    scopus 로고
    • Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: Clinical characteristics, outcomes, and incidences
    • 20197759
    • Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol. 2010;105(4):866-75.
    • (2010) Am J Gastroenterol , vol.105 , Issue.4 , pp. 866-875
    • Chang, L.1    Tong, K.2    Ameen, V.3
  • 94
    • 52149088774 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome
    • 18618371 1:CAS:528:DC%2BD1cXhtFCiu77I
    • Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 2008;43(10):1202-11.
    • (2008) Scand J Gastroenterol , vol.43 , Issue.10 , pp. 1202-1211
    • Matsueda, K.1    Harasawa, S.2    Hongo, M.3    Hiwatashi, N.4    Sasaki, D.5
  • 95
    • 84921938360 scopus 로고    scopus 로고
    • Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea
    • (pii: S1542-3565(13)01830-2)
    • Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2013 (pii: S1542-3565(13)01830-2).
    • (2013) Clin Gastroenterol Hepatol
    • Fukudo, S.1    Ida, M.2    Akiho, H.3    Nakashima, Y.4    Matsueda, K.5
  • 97
    • 84891887937 scopus 로고    scopus 로고
    • Systematic review with meta-analysis: Highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation
    • 24308797 1:CAS:528:DC%2BC2cXnt1ejsA%3D%3D
    • Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murad MH. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014;39(3):239-53.
    • (2014) Aliment Pharmacol Ther , vol.39 , Issue.3 , pp. 239-253
    • Shin, A.1    Camilleri, M.2    Kolar, G.3    Erwin, P.4    West, C.P.5    Murad, M.H.6
  • 99
    • 82955195427 scopus 로고    scopus 로고
    • Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation
    • 21876564 1:CAS:528:DC%2BC3MXhsFKmsrrP
    • Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106:2154-64.
    • (2011) Am J Gastroenterol , vol.106 , pp. 2154-2164
    • Wong, B.S.1    Camilleri, M.2    McKinzie, S.3
  • 100
    • 84865402994 scopus 로고    scopus 로고
    • Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome - A pilot study
    • 22783919 1:CAS:528:DC%2BC38Xhtl2ht7nO
    • Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome - a pilot study. Scand J Gastroenterol. 2012;47(10):1159-64.
    • (2012) Scand J Gastroenterol , vol.47 , Issue.10 , pp. 1159-1164
    • Tuteja, A.K.1    Fang, J.C.2    Al-Suqi, M.3    Stoddard, G.J.4    Hale, D.C.5
  • 102
    • 84921938481 scopus 로고    scopus 로고
    • Randomized placebo controlled multicenter trial of mesalazine in patients with irritable bowel syndrome (IBS)
    • Barbara G, Cremon C, Bellacosa L, De Giorgio R, Stanghellini V, Corinaldesi R. Randomized placebo controlled multicenter trial of mesalazine in patients with irritable bowel syndrome (IBS). Gastroenterology. 2014;146(5):S-124.
    • (2014) Gastroenterology , vol.146 , Issue.5 , pp. 124
    • Barbara, G.1    Cremon, C.2    Bellacosa, L.3    De Giorgio, R.4    Stanghellini, V.5    Corinaldesi, R.6
  • 103
    • 37149041916 scopus 로고    scopus 로고
    • Clinical trial: Dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome
    • 17973974 1:CAS:528:DC%2BD1cXitVKrsbY%3D
    • Leventer SM, Raudibaugh K, Frissora CL, Kassem N, Keogh JC, Phillips J, Mangel AW. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27(2):197-206.
    • (2008) Aliment Pharmacol Ther , vol.27 , Issue.2 , pp. 197-206
    • Leventer, S.M.1    Raudibaugh, K.2    Frissora, C.L.3    Kassem, N.4    Keogh, J.C.5    Phillips, J.6    Mangel, A.W.7
  • 105
    • 45549083888 scopus 로고    scopus 로고
    • Clinical trial: Asimadoline in the treatment of patients with irritable bowel syndrome
    • 18466359 1:CAS:528:DC%2BD1cXps1Gmt7k%3D
    • Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28(2):239-49.
    • (2008) Aliment Pharmacol Ther , vol.28 , Issue.2 , pp. 239-249
    • Mangel, A.W.1    Bornstein, J.D.2    Hamm, L.R.3    Buda, J.4    Wang, J.5    Irish, W.6    Urso, D.7
  • 106
    • 57649120166 scopus 로고    scopus 로고
    • Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients
    • 19092244 1:CAS:528:DC%2BD1MXjtVykt7s%3D
    • Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion. 2008;78(4):180-6.
    • (2008) Digestion. , vol.78 , Issue.4 , pp. 180-186
    • Mangel, A.W.1    Chaturvedi, P.2
  • 107
    • 85027944400 scopus 로고    scopus 로고
    • Reduced hippocampal glutamate-glutamine levels in irritable bowel syndrome: Preliminary findings using magnetic resonance spectroscopy
    • 21502999 1:CAS:528:DC%2BC3MXps12ksLs%3D
    • Niddam DM, Tsai SY, Lu CL, Ko CW, Hsieh JC. Reduced hippocampal glutamate-glutamine levels in irritable bowel syndrome: preliminary findings using magnetic resonance spectroscopy. Am J Gastroenterol. 2011;106(8):1503-11.
    • (2011) Am J Gastroenterol. , vol.106 , Issue.8 , pp. 1503-1511
    • Niddam, D.M.1    Tsai, S.Y.2    Lu, C.L.3    Ko, C.W.4    Hsieh, J.C.5
  • 108
    • 77958133085 scopus 로고    scopus 로고
    • Pregabalin: An alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia
    • 20586522
    • Arnold L, Mease P, Silverman S. Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia. Am J Manag Care. 2010;16(5 Suppl):S138-43.
    • (2010) Am J Manag Care. , vol.16 , Issue.5 , pp. 138-S143
    • Arnold, L.1    Mease, P.2    Silverman, S.3
  • 109
    • 34548127061 scopus 로고    scopus 로고
    • Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome
    • 17446306 1:CAS:528:DC%2BD2sXhtVKgsbnK 1954959
    • Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56(9):1218-25.
    • (2007) Gut. , vol.56 , Issue.9 , pp. 1218-1225
    • Houghton, L.A.1    Fell, C.2    Whorwell, P.J.3    Jones, I.4    Sudworth, D.P.5    Gale, J.D.6
  • 110
    • 78349268748 scopus 로고    scopus 로고
    • Differential responding of autonomic function to histamine H1 antagonism in irritable bowel syndrome
    • 20667004 1:CAS:528:DC%2BC3cXhs1WrtrfN (e335)
    • Hattori T, Watanabe S, Kano M, Kanazawa M, Fukudo S. Differential responding of autonomic function to histamine H1 antagonism in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(12):1284-91 (e335).
    • (2010) Neurogastroenterol Motil , vol.22 , Issue.12 , pp. 1284-1291
    • Hattori, T.1    Watanabe, S.2    Kano, M.3    Kanazawa, M.4    Fukudo, S.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.